Nur Nicholson Sells 20,350 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 20,350 shares of the company’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $44.27, for a total value of $900,894.50. Following the transaction, the insider now directly owns 53,284 shares in the company, valued at approximately $2,358,882.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Apellis Pharmaceuticals Stock Up 2.8 %

Shares of APLS stock traded up $1.30 during trading hours on Tuesday, hitting $48.30. 7,062,968 shares of the company were exchanged, compared to its average volume of 2,788,841. The company has a market capitalization of $5.69 billion, a PE ratio of -8.48 and a beta of 1.08. Apellis Pharmaceuticals, Inc. has a 52 week low of $19.83 and a 52 week high of $94.75. The business has a 50 day moving average of $39.66 and a two-hundred day moving average of $66.62. The company has a current ratio of 5.11, a quick ratio of 4.52 and a debt-to-equity ratio of 0.27.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Monday, July 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.33. The firm had revenue of $95.00 million during the quarter, compared to analysts’ expectations of $70.38 million. Apellis Pharmaceuticals had a negative return on equity of 212.82% and a negative net margin of 356.02%. The company’s revenue was up 482.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.46) EPS. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -4.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

APLS has been the topic of several recent research reports. JPMorgan Chase & Co. lowered shares of Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $72.00 to $60.00 in a research note on Thursday, August 3rd. Stifel Nicolaus raised their price objective on shares of Apellis Pharmaceuticals from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday, August 29th. Raymond James dropped their target price on shares of Apellis Pharmaceuticals from $156.00 to $89.00 and set a “strong-buy” rating for the company in a research report on Tuesday, August 1st. Needham & Company LLC restated a “buy” rating and issued a $60.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, August 30th. Finally, Wedbush reiterated a “neutral” rating and issued a $29.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, August 23rd. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $66.13.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of APLS. Price T Rowe Associates Inc. MD grew its stake in shares of Apellis Pharmaceuticals by 66.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,590,040 shares of the company’s stock worth $302,760,000 after acquiring an additional 1,840,498 shares in the last quarter. Norges Bank acquired a new stake in Apellis Pharmaceuticals in the 4th quarter valued at $54,164,000. FMR LLC lifted its position in Apellis Pharmaceuticals by 45.6% during the 1st quarter. FMR LLC now owns 2,125,437 shares of the company’s stock worth $140,194,000 after buying an additional 665,274 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Apellis Pharmaceuticals by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 8,569,170 shares of the company’s stock worth $435,400,000 after buying an additional 652,071 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Apellis Pharmaceuticals by 20.3% in the 2nd quarter. State Street Corp now owns 3,496,925 shares of the company’s stock valued at $158,131,000 after acquiring an additional 590,469 shares in the last quarter. Institutional investors and hedge funds own 90.43% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).